Zolgensma, an adeno-associated virus vector-based, one-time gene therapy administered via intravenous infusion, is the first and only FDA-approved gene therapy for SMA. 
Considerations for transplantation in the era of newer therapies for the treatment of hereditary ATTR amyloidosis.

SAP Partner Banner